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Summary
Polycythemia vera (PV), essential thrombocythemia (ET), and myeloid metaplasia with myelofibrosis (MMM) are clonal
disorders arising from hematopoietic progenitors. An internet-based protocol was used to collect clinical information and
biological specimens from patients with these diseases. High-throughput DNA resequencing identified a recurrent somatic
missense mutation JAK2V617F in granulocyte DNA samples of 121 of 164 PV patients, of which 41 had homozygous and
80 had heterozygous mutations. Molecular and cytogenetic analyses demonstrated that homozygous mutations were due
to duplication of the mutant allele. JAK2V617F was also identified in granulocyte DNA samples from 37 of 115 ET and 16
of 46 MMM patients, but was not observed in 269 normal individuals. In vitro analysis demonstrated that JAK2V617F is a
constitutively active tyrosine kinase.S I G N I F I C A N C E
Although the myeloproliferative disorders (MPD) PV, ET, and MMM are thought to be caused by acquired somatic mutation in
hematopoietic progenitors, the genetic basis for these diseases has not been known. We report that hematopoietic cells from a
majority of patients with PV and a significant number of patients with ET and MMM possess a recurrent somatic activating mutation
in the JAK2 tyrosine kinase. Inhibition of the JAK2V617F kinase with a small molecule inhibitor leads to inhibition of proliferation of
hematopoietic cells, suggesting that the JAK2 tyrosine kinase is a potential target for pharmacologic inhibition in patients with PV,
ET, and MMM.Introduction
Myeloproliferative disorders (MPD) include polycythemia vera
(PV), essential thrombocythemia (ET), myeloid metaplasia with
myelofibrosis (MMM), chronic myelogenous leukemia (CML),
chronic myelomonocytic leukemia (CMML), hypereosinophilic
syndrome (HES), and systemic mast cell disease (SMCD). A
clonal population of hematopoetic cells has been observed in
patients with PV, ET, and MMM, indicating that these diseasesCANCER CELL : APRIL 2005 · VOL. 7 · COPYRIGHT © 2005 ELSEVIER INCare caused by acquired somatic mutation in hematopoietic
progenitors, but the genetic basis has not been known (Adam-
son et al., 1976; Gilliland et al., 1991). Reports of decreased
expression of the thrombopoietin receptor in platelets from pa-
tients with PV, and of overexpression of the antiapoptotic pro-
tein Bcl-x in PV (Moliterno et al., 1998; Silva et al., 1998), sug-
gest that abnormalities in signal transduction and in apoptosis
are important in the pathogenesis of PV and other MPD. In
addition, activating mutations in the erythropoietin (EPO) re-. DOI 10.1016/j.ccr.2005.03.023 387
A R T I C L Eceptor and in the von Hippel-Lindau (VHL) protein have been
identified in a subset of patients with familial and congenital
polycythemia, but these genes have not been pathogenetically
linked to sporadic PV or other MPD (Arcasoy et al., 1997; Kra-
lovics et al., 1997; Pastore et al., 2003; Sokol et al., 1995).
In contrast to PV, ET, and MMM, the molecular pathogenesis
of several other MPD has been well characterized, and is fre-
quently attributable to mutations that result in constitutive acti-
vation of a protein tyrosine kinase. Furthermore, these mutant
kinases have proven to be good candidates for molecularly
targeted therapy. The paradigm established by Druker and col-
leagues is the BCR-ABL gene rearrangement associated with
CML (Bartram et al., 1983), which is effectively treated with
the small molecule tyrosine kinase inhibitor imatinib (Gleevec)
(Druker et al., 2001). In addition to ABL, imatinib also inhibits
PDGFR family members, which has led to the successful treat-
ment of patients with PDGFRB rearrangements and CMML
(Golub et al., 1994) and patients with the FIP1L1-PDGFRA fu-
sion and HES (Cools et al., 2003). Other examples of mutant
tyrosine kinases in MPD include FGFR1 gene rearrangements
in stem cell myeloproliferative disorders (Xiao et al., 1998), and
activating mutations in KIT in systemic mast cell disease (Fur-
itsu et al., 1993). Thus, tyrosine kinases are often mutated in
MPD, and have been demonstrated to be excellent targets for
therapeutic intervention.
These observations suggest the hypothesis that activating
mutations in tyrosine kinases are important in the pathogenesis
of PV, ET, and MMM. We used an internet-based clinical proto-
col and high-throughput DNA sequence analysis to screen for
tyrosine kinase mutations in PV, ET, and MMM.
Results
Myeloproliferative disorders study
586 patients expressed interest in the study, and 345 partici-
pants consented to participate and returned the questionnaire
and at least one biologic sample (Supplemental Figure S1). The
clinical characteristics of the 345 participants are shown in Ta-
ble 1. The median age of the case series was 59 (range 31–84
years) and the median age at diagnosis was 52 (range 17–78
years). The majority of patients were female (59%), and the
majority of patients were Caucasian (94%). By patient self-
report, the cross-sectional study included 171 patients with PV
(50%), 126 patients with ET (37%), and 46 patients with MMM
(13%). 2 patients did not provide a specific diagnosis and were
classified as MPD “not otherwise specified.” The internet re-
cruitment method selected for a highly educated and affluent
population; 60% of participants were college graduates, and
47% reported incomes greater than $75,000/year. All patients
provided blood samples, and 338 patients provided buccal
swabs. Of 345 blood samples, 327 (95%) yielded sufficient
DNA for sequence analysis. We retrospectively abstracted
medical records to verify patient self-reported diagnoses. Med-
ical records were available for 304 patients, and we were able
to verify self-reported diagnosis for 249/257 (97%) patients
who provided sufficient medical records (Supplemental Data,
section “MPD patients with confirmed diagnoses”). These re-
sults demonstrate the feasibility of using the internet to recruit
and enroll patients in a clinical protocol, and that patient self-
report correlates with confirmed diagnosis by medical record
abstraction.388Table 1. Patient characteristics
Characteristic
Total, n 345
Male/female, n 142/203
Median age, years (range) 59 (31–84)
Median age at diagnosis, years (range) 52 (17–78)
Race, n (%)
Caucasian 325 (94)
Hispanic 10 (2.9)
Asian 4 (1.2)
Black/African-American 1 (0.3)
Multiracial or other 5 (1.5)
Self-reported diagnosis, n (%)
PV 171 (50)
ET 126 (37)
MMM 46 (13)
MPD, NOS 2 (0.6)
Median disease duration, months (range)
Case series 68 (3–549)
PV 60 (4–433)
ET 79 (9–549)
MMM 64 (14–379)
Prior thrombosis, n (%)
Case series 76 (22)
PV 31 (18)
ET 40 (32)
MMM 5 (11)
PV, polycythemia vera; ET, essential thrombocythemia; MMM, myeloid metaplasia
with myelofibrosis.JAK2 mutations in myeloproliferative disorders
93 granulocyte DNA samples from PV patients were initially
evaluated for sequence alterations in the activation loops and
known autoinhibitory domains of 85 tyrosine kinases, and we
identified a recurrent guanine to thymine substitution in JAK2
exon 14 that results in a valine to phenylalanine substitution at
codon 617 within the JH2 autoinhibitory domain (Figures 1A–
1C). Sequence analysis of the entire open reading frame of
JAK2 in these 93 PV patients identified novel germline nonsyn-
onymous substitutions (R1063H in 3 patients, R340Q in 1 pa-
tient, R564L in one patient), but we did not identify additional
somatic mutations in JAK2. We did not identify somatic muta-
tions in the other tyrosine kinases analyzed. We subsequently
sequenced exon 14 of JAK2 in all patients in the case series
with self-reported PV, ET, and MMM (Table 2). Analysis of gran-
ulocyte DNA from 164 PV patients identified heterozygous
JAK2V617F mutations in 80 (49%) patients and homozygous
mutations in 41 (25%) patients. Of 115 patients with ET, 34
(30%) were heterozygous and 3 (3%) were homozygous for the
JAK2V617F allele. Of 46 patients with MMM 12 (26%) were
heterozygous and 4 (9%) were homozygous for the JAK2V617F
allele. Sequence analysis of cDNA from selected PV patients
confirmed expression of both mutant and wild-type alleles in
heterozygous patients.
Analysis of DNA derived from buccal mucosa
Buccal swabs were provided by 338 patients, and 313 buccal
DNA samples were evaluable for the JAK2V617F mutation.
301/313 (96%) buccal DNA samples did not contain the
JAK2V617F allele, but heterozygous JAK2V617F alleles were
identified in buccal DNA samples from 11 patients with PV and
one patient with MMM. In 7 cases, PV patients had a heterozy-CANCER CELL : APRIL 2005
A R T I C L EFigure 1. JAK2V617F mutations in polycythemia
vera samples
A: Forward (middle trace) and reverse (lower
trace) sequence demonstrating a heterozygous
guanine to thymine substitution (arrows) present
in granulocyte DNA from a patient with PV that
is not present in matched normal DNA (upper
trace).
B: Forward (middle trace) and reverse (lower
trace) sequence demonstrating a homozygous
guanine to thymine substitution (arrows) present
in granulocyte DNA from a patient with PV that
is not present in matched normal DNA (upper
trace).
C: Forward (middle trace) and reverse (lower
trace) sequence demonstrating a homozygous
guanine to thymine substitution (arrows) present
in granulocyte DNA from a patient with PV that
is present as a heterozygous allele in matched
normal DNA (upper trace).
D: DNA sequence and protein translation for
both the wild-type and mutant JAK2 alleles. The
guanine to thymine substitution results in a va-
line to phenylalanine substitution at codon 617.gous allele in their buccal DNA and a homozygous allele in
granulocyte DNA, consistent with loss of heterozygosity at this
locus (Figure 1C). In the remaining cases, buccal and granulo-
cyte DNA were heterozygous. The JAK2V617F allele was not
identified in buccal DNA from any patients with ET. These data
indicate the JAK2V617F is an acquired somatic mutation in the
majority of patients with MPD.
V617F genotyping in the general population
To assess the prevalence of the V617F allele in normal individ-
uals of Caucasian descent, and in the general population, weCANCER CELL : APRIL 2005analyzed the JAK2 genotype in a standard panel of 270 sam-
ples collected by the International HapMap Consortium (The
International HapMap Consortium, 2003). The samples were
collected from four populations: CEPH (Centre d’Etude du
Polymorphism Humain)—Utah residents with Caucasian an-
cestry from Northern and Western Europe (30 parent-offspring
trios, or 120 independent chromosomes); Yoruba, Nigeria (30
parent-offspring trios, or 120 independent chromosomes); Han
Chinese (45 unrelated individuals, or 90 independent chromo-
somes); and Japanese (45 unrelated individuals, or 90 inde-
pendent chromosomes). Pilot matrix-assisted laser desorption/389
A R T I C L ETable 2. Mutational status by disease
Mutation Total (n = 3451) PV (n = 1642) ET (n = 1153) MMM (n = 46)
None 151 (44) 43 (26) 78 (68) 30 (65)
Heterozygous 126 (36) 80 (49) 34 (29) 12 (26)
Homozygous 48 (14) 41 (25) 3 (3) 4 (9)
Unknown 20 (6)
Number and (percent) are indicated.
1Two subjects have MPD, not otherwise specified.
27 additional patients were not evaluable for JAK2V617F mutations.
311 additional patients were not evaluable for JAK2V617F mutations.ionization time-of-flight mass spectrometry (MALDI-TOF MS)
genotyping of 95 granulocyte and buccal DNA samples from
our case series correctly identified all JAK2V617F alleles iden-
tified by conventional DNA sequencing. High-confidence geno-
types were obtained using the MALDI-TOF MS assay for 269
of the 270 HapMap samples (Figure 2A). All 269 samples were
homozygous for the wild-type V617 allele. Comparing the fre-
quency of the JAK2V617F allele in buccal DNA from patients
with PV, 94% of whom are Caucasian, with unaffected individ- homozygous JAK2V617F mutations. Seven patients were het-
Figure 2. Genotypic analysis of the JAK2V617F
allele
A: MALDI-TOF MS genotypic analysis for the
JAK2V617F allele in a PV patient with a hetero-
zygous JAK2V617F mutation (upper trace) and
for a normal individual from the HapMap Panel
(middle trace). The arrows denote the mass of
the genotyping probe, the wild-type V617 al-
lele, and the JAK2V617F mutant allele, respec-
tively.
B: Sequence traces of JAK2 exon 6 from two pa-
tients with homozygous JAK2V617F mutations
demonstrating loss of heterozygosity at the JAK2
locus. The arrows show heterozygous alleles (up-
per traces) at a known polymorphism in the
buccal DNA of both patients with loss of hetero-
zygosity in the granulocyte DNA (bottom traces)
in both cases.
C: Quantitative PCR for the JAK2 locus relative
to Factor VIII for 4 patients, each with wild-type
JAK2 (green), heterozygous JAK2V617F muta-
tions (blue), or homozygous JAK2V617F muta-
tions (yellow). Error bars denote the standard
deviation for each sample measured in tripli-
cate. All samples tested showed two copies of
the JAK2 locus, consistent with mitotic recombi-
nation in homozygotes.
D: FISH analysis of one patient with a known ho-
mozygous JAK2V617F mutation with probes up-
stream (red) and downstream (green) of the
JAK2V617F mutation, demonstrating two copies
of the JAK2 locus, also consistent with mitotic re-
combination.390uals in the CEPH panel, the difference was significant (p =
0.021 by Fisher’s exact test).
Loss of heterozygosity at the JAK2 locus
is due to mitotic recombination
We amplified and sequenced a synonymous single nucleotide
polymorphism in JAK2 exon 6 (refSNP ID: rs2230722) 22.8 kb
upstream of JAK2V617F in buccal DNA from 17 patients withCANCER CELL : APRIL 2005
A R T I C L Eerozygous for the polymorphism in their buccal DNA, and all 7
demonstrated loss of heterozygosity in their granulocyte DNA
(Figure 2B). To distinguish between deletion of the wild-type
allele and mitotic recombination, we performed quantitative
genomic polymerase chain reaction (PCR) on 32 granulocyte
DNA samples, including 16 samples from patients with homo-
zygous JAK2V617F mutations (Figure 2C). In all cases ana-
lyzed there were two copies of the JAK2 locus, consistent with
reduplication of the mutant allele. Fluorescent in situ hybridiza-
tion (FISH) analysis confirmed the presence of two copies of
the JAK2 locus in 35 patients, including in 12 patients with
homozygous JAK2V617F mutations (Figure 2D).
Comparison of genotype and clinical outcome
Considering the case series as a whole, no association was
observed between mutational status and current age, age
at diagnosis, gender, race, comorbidity, physical functioning,
prior thrombosis, or self-reported family history (data not
shown). However, subjects with PV were more likely to have a
detectable mutation in their granulocyte DNA (74% versus
33%, p < 0.0001) or buccal DNA (7% versus 1%, p = 0.003)
than subjects with either ET or MMM. In addition, within the
PV subset, women were more likely than men to have either a
heterozygous or homozygous mutation (83% versus 64%, p =
0.004). A homozygous mutation was associated with a longer
duration of disease than either heterozygous or no mutation
among patients with PV or ET (median 89 versus 61 months,
p = 0.008), but not MMM. No association was seen between
the presence of the JAK2V617F allele in buccal DNA and self-
reported family history of MPD.
Structural and functional analysis of JAK2V617F
The JH2 (pseudokinase) domain lacks several residues that are
critical for phosphotransferase activity, but is expected to
adopt the overall protein architecture that is characteristic of
bona fide tyrosine and serine/threonine kinases. Using the
SwissModel automated comparative protein modeling server,
we constructed a homology model of the JAK2 JH2 domain
using the structure of Bruton’s tyrosine kinase (Mao et al.,
2001) (PDB accession code 1K2P), which has a 26% identity
to the JAK2 JH2 domain. Val617 is expected to lie on the upper
surface of the N-terminal lobe of the JH2 domain, at the
C-terminal end of strand β4 (Figure 3A). Modeling suggests
that this residue is largely solvent-exposed, and that substitu-
tion with phenylalanine is unlikely to significantly destabilize the
fold of the domain. This residue is a component of a surface
patch that is conserved among JAK pseudokinase domains.
In functional assays, JAK2V617F, but not wild-type JAK2,
was a constitutively activated tyrosine kinase as assessed by
autophosphorylation (Figure 3B) when expressed in 293T cells.
When increasing amounts of wild-type JAK2 were coexpressed
with JAK2V617F, there was no change in the level of JAKV617F
tyrosine phosphorylation (Figure 3C), suggesting that the wild-
type allele does not interfere with constitutive activation of
JAK2V617F. Expression of JAK2V617F, but not wild-type JAK2,
in Ba/F3-EPOR cells conferred erythropoietin hypersensitivity
and erythropoietin-independent survival, consistent with in vi-
tro erythroid colony formation in patients with PV (Figure 3D)
(Prchal and Axelrad, 1974; Zanjani et al., 1977).
Sequence analysis of the HEL human erythroleukemia cell
line identified a homozygous JAK2V617F mutation in this cellCANCER CELL : APRIL 2005line (Figure 4A), but not in K562, MOLT16, or RPMI-8402
cell lines. JAK2V617F was constitutively tyrosine-phosphory-
lated in HEL cells, as were downstream effectors STAT5 and
ERK (Figure 4B). Furthermore, treatment with a small molecule
inhibitor of JAK2 (Thompson et al., 2002) showed a dose-
dependent inhibition of proliferation of HEL cells, but not leuke-
mia cell lines K562 (Figure 4C), MOLT16, or RPMI-8402 (data
not shown). Inhibition of proliferation corresponded with re-
duced phosphorylation of JAK2 and STAT5 (Figure 4D). More-
over, treatment of HEL cells with the JAK2 inhibitor resulted in
induction of apoptosis, which was not observed in the control
cell line K562 that is known to express the constitutively active
tyrosine kinase BCR-ABL (Figure 4E). These findings indicate
that JAK2V617F is a constitutively activated tyrosine kinase
that enhances hematopoietic cell proliferation and survival, and
is sensitive to inhibition with small molecule inhibitors.
Discussion
We identified JAK2V617F mutations in granulocyte DNA from
~3/4 of PV patients, as well as in a substantial fraction of ET
and MMM patients. Sequence analysis showed wild-type JAK2
sequence in DNA from buccal mucosa of 301/313 (96%)
evaluable patients, providing strong genetic evidence that
JAK2V617F is an acquired somatic disease allele that arises
in hematopoietic progenitors and confers a selective growth
advantage. In addition, a significant proportion of patients had
homozygous mutations due to mitotic recombination, as has
been described in patients with homozygous FLT3 mutations
with retention of two copies of the FLT3 locus (Frohling et al.,
2002). Since JAK2V617F is an acquired mutation, duplication
of the mutant allele is most likely due to mitotic recombination.
This provides genetic evidence that JAK2V617F confers a fur-
ther selective advantage when two mutant alleles of JAK2 are
present.
The JAK2V617F mutation constitutively activates the JAK2
tyrosine kinase as assessed by anti-phosphotyrosine blotting.
The increase in phosphotyrosine content cannot be explained
as a consequence of overexpression alone, in that wild-type
JAK2 is not tyrosine-phosphorylated when expressed at com-
parable levels. Selection for cells with homozygous JAK2V617F
alleles suggests either that the native JAK2 has dominant in-
terfering activity for the mutant JAK2V617F, or that duplication
of the allele confers a selective advantage compared to cells
with only one mutant allele. The observation that expression of
increasing levels of wild-type JAK2 has no effect on phospho-
tyrosine content of JAKV617F in 293T cells favors the latter
hypothesis, but should also be evaluated in hematopoietic
contexts in which the erythropoietin receptor (EPOR) is ex-
pressed as well.
JAK2V617F, but not JAK2, confers factor-independent growth
to Ba/F3 cells stably transduced with the EPOR, as well as
hypersensitivity to erythropoietin. These data are in conso-
nance with observations in PV patients in which erythropoietin-
independent BFU-E may be generated, and which show hyper-
sensitivity to erythropoietin (Prchal and Axelrad, 1974; Zanjani
et al., 1977). In addition, we report that the HEL cell line con-
tains a homozygous JAK2V617F mutation. HEL cells, but not
cells with wild-type JAK2, undergo apoptotic cell death in re-
sponse to a JAK inhibitor. Furthermore, activity of JAK2V617F
and the downstream effector STAT5, as assessed by phospho-391
A R T I C L EFigure 3. Structure and function of the JAK2V617F protein
A: Homology model of the JH2 (pseudokinase) domain of human JAK2.
The model was constructed using the SwissModel automated comparative
protein modeling server using the JAK2 pseudokinase domain sequence
and the crystallographic structure of Bruton’s tyrosine kinase (PDB acces-
sion code 1K2P) (Mao et al., 2001). Although several residues critical for
kinase activity are not conserved, the pseudokinase domain is expected392of JAK2 is consistent with this possibility (see Supplemental
to retain the essential features of the protein kinase fold, including the
smaller β sheet-rich N-lobe and the larger, mostly helical C-lobe. Val 617
(indicated in red) is expected to lie exposed on the upper surface of the
N-lobe at the C-terminal end of strand β4. Note that Val617 lies at the edge of
a conserved patch that includes residues of the C-helix and the N-terminal
portion of the region corresponding to the activation loop (colored or-
ange). We hypothesize that this residue participates in interdomain interac-
tions that inhibit JAK catalytic activity. The figure was made using the pro-
gram SETOR (Evans, 1993).
B:Western blot experiments with 293T cells. The upper blots show phosphor-
ylation status of JAK2 in 293T cells overexpressing wild-type JAK2 or the
JAK2V617F protein (left panel), or in 293T cells with lower level expression
of wild-type JAK2, JAK2V617F, or empty vector (right panel). These blots
demonstrate a marked increase in JAK2 autophosphorylation in cells ex-
pressing the JAK2V617F mutant. The lower panels show similar levels of ex-
pression of JAK2 in the cells transfected with wild-type or mutant JAK2,
respectively.
C: Expression of increasing amounts of wild-type JAK2 does not influence
tyrosine phosphorylation of JAK2V617F, indicating that the wild-type allele
does not have dominant negative inhibitory activity. From left to right, 0,
300, 600, and 900 ng of the wild-type JAK2 expression vector was cotrans-
fected with 300 ng of the JAK2V617F expression vector. The upper blot
shows no change in JAK2 phosphorylation, while the lower blot shows
increasing expression of JAK2.
D: Erythropoietin hypersensitivity in Ba/F3-EPOR cells expressing JAK2V617F.
2.5 × 105 Ba/F3-EPOR cells stably expressing wild-type JAK2 or JAK2V617F
were cultured in triplicate in RPMI/10% FCS containing EPO 1 U/ml, 0.01
U/ml, 0.001 U/ml, or in the absence of EPO for 7 days. Error bars denote the
standard deviation for each sample measured in triplicate. There are an
increased number of viable cells at EPO 1 U/ml in the Ba/F3-EPOR cells
transfected with JAK2V617F relative to wild-type JAK2. At limiting (0.01 and
0.001 U/ml) concentrations of EPO and in cytokine-free media, there were
no viable Ba/F3-EPOR cells expressing wild-type JAK2, whereas Ba/F3-EPOR
cells expressing JAK2V617F were viable at all concentrations of EPO tested
and in the absence of EPO.tyrosine content, are also inhibited. These data collectively in-
dicate that JAK2V617F is a gain-of-function allele that results
in expression of a constitutively activated tyrosine kinase that
confers predicted growth properties to hematopoietic cells,
and is sensitive to small molecule inhibition.
The mechanism of activation of JAK2 by the V617F substitu-
tion is not known, but the JH2 pseudokinase domain is thought
to inhibit the activity of the JAK2 kinase (JH1) domain, in that
deletion of the JH2 domain leads to a marked increase in JAK2
kinase activity (Saharinen et al., 2000). Autoinhibition of recep-
tor tyrosine kinases is often accomplished by residues within
the kinase domain or by immediately adjacent juxtamembrane
or C-terminal sequences, with activating mutations in these re-
gions identified in Kit, Flt-3, and EGFR (Furitsu et al., 1993;
Lynch et al., 2004; Nakao et al., 1996; Paez et al., 2004). In
contrast, autoinhibition of nonreceptor tyrosine kinases and
phosphatases, such as JAK2, results from interdomain interac-
tions with activating mutations often arising in interdomain in-
terfaces. For example, mutations in the SH2 and SH3 domain
interfaces in BCR-ABL relieve autoinhibition of the kinase do-
main (Smith et al., 2003), and activating mutations in the
SHP-2 phosphatase seen in Noonan’s syndrome and in a sub-
set of juvenile myelomonocytic leukemias disrupt the autoin-
hibitory SH2 domain/phosphatase domain interface (Tartaglia
et al., 2001; Tartaglia et al., 2003). We propose that the V617F
substitution in the pseudokinase domain of JAK2 releases au-
toinhibitory interdomain interactions, leading to constitutive ki-
nase activation. Structural modeling of the JH1-JH2 domainsCANCER CELL : APRIL 2005
A R T I C L EFigure 4. Functional activity of JAK2V617F in the
HEL cell line
A: The JAK2V617F homozygous mutation in HEL
cells.
B: Phosphorylation of JAK2, STAT5, and ERK1/2 ki-
nases in the HEL cell line.
C: Dose-dependent inhibition of growth of the
HEL cell line but not the K562 cell line with
increasing concentrations of JAK inhibitor I. Error
bars denote the standard deviation for each
sample measured in triplicate.
D: Reduction in JAK2 phosphorylation and inhi-
bition of STAT5 phosphorylation in HEL cells
treated with increasing doses of JAK inhibitor I.
Phospho-JAK2 was not expressed in K562 cells,
nor was any effect observed on STAT5 phosphor-
ylation in K562 cells.
E: Induction of apoptosis by JAK inhibitor I in HEL
cells, but not K562 cells. The percentage of
apoptotic cells (lower right quadrant) after
treatment with 1–2 µM JAK inhibitor I was higher
in HEL cells (15%–46%) versus K562 cells (2%–
3.1%).Data, section “Predicted model of the JAK2V617F allele.”) (Lin-
dauer et al., 2001). Solution of the JAK2 JH1-JH2 structure will
be required to confirm this possibility, and may also provide
insight into the selection for the JAK2V617F mutation, as op-
posed to other activating alleles, in all patients.
The observation that a single mutant allele is present in a
significant proportion of PV, ET, and MMM is also of interest
in that these are distinct clinical entities. This is similar to the
association of a single disease allele, the BCR-ABL gene re-
arrangement, with a spectrum of hematologic malignancies
that includes CML, CML in blast crisis, de novo AML, and B
cell ALL. The basis for phenotypic pleiotropy in patients with
the same disease allele could include host modifiers, differ-
ences in the hematopoietic progenitor in which the mutation
occurs, or as yet unidentified second mutations that contribute
to phenotype. However, there is also significant clinical overlap
between the MPD syndromes. For example, patients with ET
may progress to PV, patients with PV who are iron-deficient
may present with signs and symptoms of ET, and patients with
ET or PV may progress to develop severe myelofibrosis. It will
also be of interest to determine whether there are substantive
differences in patterns of global gene expression between
MMM, PV, and ET patients, but these genotypic data suggest
these diseases may be more alike than disparate.
A significant proportion of PV, ET, or MMM patients (26%, 68%,
and 65%, respectively) do not have detectable JAK2V617F
mutations in granulocyte DNA. This observation may be ex-CANCER CELL : APRIL 2005plained by disease alleles other than JAK2V617F. We did not
observe additional JAK2 mutations in PV, nor were mutations
detected in the activation loop or in the JH2 domain of JAK1,
JAK3, or TYK2, respectively (data not shown). High-throughput
sequencing combined with other genome-wide screening
methods may eventually identify other mutations. Alternatively,
it is possible that patients lacking the JAK2V617F mutation
may be false negatives due to sequencing granulocyte DNA
in patients with erythroid (PV) or megakaryocytic (ET) lineage
diseases. Mutational analysis of purified hematopoietic pro-
genitors from patients with each of these diseases should re-
solve this question and may also identify the target cell for
transformation.
Although nearly all patients had wild-type JAK2 alleles in
DNA derived from buccal swabs, 12 patients (4%) had V617F
substitutions. Further study will be required to determine
whether the JAK2V617F allele is a heritable disease allele in
families at increased risk for PV and other MPD. Our study
protocol did not permit for followup with family members for
patients who reported family histories of MPD, but ultimately it
should be possible to determine whether JAKV617F can be
transmitted in the germline. Familial predisposition to PV and
other MPD has been described, although the genetic basis for
predisposition is not known (Kralovics et al., 2003). Inherited
mutant alleles that activate kinases and other signaling inter-
mediates in cancer have been described, including PTPN11 in
Noonan’s syndrome associated with juvenile myelomonocytic393
A R T I C L Eleukemia and RET mutations in multiple endocrine neoplasia
type II (Mulligan et al., 1993; Tartaglia et al., 2001). The obser-
vation that patients may carry heterozygous JAK2V617F alleles
in their germline but not develop clinical disease until later in
life suggests that the JAK2V617F allele may be a less potent
disease allele than other inherited disease alleles; this has been
observed with specific RET mutations in multiple endocrine
neoplasia type II which often do not manifest until later in life
(Gimm et al., 2002).
The identification of JAK2 mutations in MPD is consistent
with previous genetic and functional data. Loss of heterozy-
gosity due to mitotic recombination at chromosome 9p24, the
genomic locus of JAK2, has been identified in w30% of pa-
tients with PV (Kralovics et al., 2002), which is similar to the
frequency of JAK2V617F homozygous mutations in PV pa-
tients (w25%). TEL/JAK2 fusion genes have been cloned from
patients with atypical CML and ALL (Lacronique et al., 1997;
Peeters et al., 1997), and expression of the TEL/JAK2 fusion
protein in a retroviral murine bone marrow transplant model
results in a high penetrance and short latency myeloprolifera-
tive and lymphoproliferative disease (Schwaller et al., 1998).
Activating EPOR mutations that result in activation of JAK2 and
its downstream effectors have been identified in patients with
familial and congenital polycythemia (Arcasoy et al., 1997; So-
kol et al., 1995; Watowich et al., 1999). In addition, JAK2-defi-
cient mice die in utero due to defective definitive erythropoie-
sis, and JAK2-deficient myeloid progenitors do not respond to
erythropoietin, thrombopoietin, or interleukin-3 (Parganas et al.,
1998). Finally, several indirect lines of evidence have suggested
involvement of the JAK-STAT pathway in PV (Moliterno et al.,
1998; Schwartz, 1998). Taken together, these data provide ad-
ditional support for the JAK2V617Fmutation as a disease allele
in MPD.
The JAK2V617F allele may have diagnostic and therapeutic
value in myeloproliferative diseases. For example, it may be of
value as a complement to diagnostic tests, such as red blood
cell mass, in delineating PV from secondary erythrocytosis. In
addition, comprehensive genotypic analysis should ultimately
allow for the development of molecularly annotated diagnos-
tic approaches to PV, ET, and MMM, in which there is con-
siderable phenotypic overlap. Perhaps most importantly, the
JAK2V617F mutation may represent a therapeutic target in pa-
tients with MPD. Pharmacologic inhibition of activated tyrosine
Akinases is effective in treatment of several cancers (Apperley
et al., 2002; Cools et al., 2003; Demetri et al., 2002; Druker et
al., 2001; Lynch et al., 2004; Paez et al., 2004). Our data indi-
cate that JAK2V617F is a constitutively activated tyrosine ki-
nase that can also be inhibited with small molecule inhibitors
in vitro, and may be a good target for therapeutic intervention
in a subset of PV, ET, or MMM. Finally, activation of the JAK-
STAT pathway has also been reported in a spectrum of solid
tumors, and thus genotypic analysis of JAK family members in
solid tumors may also be warranted.
Experimental procedures
Harvard myeloproliferative disorders study
From January 2004 through January 2005, biologic samples and clinical
data were collected through a protocol that was approved by the Dana-
Farber Cancer Institute Institutional Review Board, and all subjects provided
written informed consent. The study was advertised through the website
http://www.mpdinfo.org. All patients 18 years or older with ET, PV, or MMM394residing in the United States who had not undergone stem cell transplanta-
tion were eligible for the study. Potential participants e-mailed investigators
indicating their initial interest, their names, and their mailing addresses. In-
formation packets including a cover letter detailing study goals and
requirements, a consent form, a release of medical records form, a self-
administered questionnaire, and a self-addressed, stamped envelope were
sent via U.S. mail to potential participants. The self-administered question-
naire consisted of 46 items, including the Medical Outcomes Study Short
Form 12 (SF12) (Ware et al., 1996) and the Katz modification of the Charlson
comorbidity index (Katz et al., 1996). Additional constructed questions col-
lected information regarding diagnosis, symptoms at presentation, and
treatment.
After signed consent forms and questionnaires were returned to investi-
gators and eligibility verified, medical records were requested for abstrac-
tion and biologic sample kits were mailed to participants. In this study de-
sign, diagnosis relied upon patient self-report. In cases where patients
indicated they had two or more diagnoses, first diagnosis was taken as the
patient’s diagnosis. If a blood sample did not yield adequate DNA, or if self-
reported diagnosis was other than PV, ET, or MMM, the patient was ex-
cluded from the genetic analysis. In order to verify validity of self-reported
diagnosis, medical records including pathology samples, laboratory values,
and physician notes were reviewed to confirm if records supported the pa-
tient’s self-reported diagnosis.
Sample collection and processing
Biological sample kits contained two 10 ml sodium heparin tubes and a
buccal swab (MasterAmp, Epicentre). Patients were asked to have two
tubes of blood drawn at the time of their next visit to their local hematolo-
gist, and sample kits were returned by overnight delivery. Blood samples
were subjected to density centrifugation with Ficoll Histopaque 1077 (Sigma
Chemical). The granulocyte layer was collected and DNA was extracted
using the QIAamp DNA Blood Maxi Kit (Qiagen). RNA was isolated using
Trizol (Invitrogen). DNA was isolated from buccal swabs using the QIAamp
DNA Mini Kit (Qiagen).
Tyrosine kinase exon sequence analysis
Primers were designed to amplify and sequence exons encoding the activa-
tion loops and autoinhibitory domains of 85 of the 90 tyrosine kinases (Man-
ning et al., 2002), with the exception of AATK, DKFZp434C1418, STYK1,
LMTK2, and LMTK3. External gene-specific primers and internal M13-
appended PCR primers for the activation loops of receptor tyrosine kinases
were identical to those previously described (Paez et al., 2004), and addi-
tional primers are listed in Supplemental Table S3. PCR products were puri-
fied (SPRI, Agencourt Bioscience Corporation), followed by bidirectional se-
quencing and sequence detection on an ABI Prism 3730 DNA Analyzer
(Applied Biosystems) using conditions previously described (Paez et al.,
2004). Sequence analysis of JAK2 exon 14 was performed by single round
of PCR amplification using primers Exon 14F (5# GTAAAACGACGGCCAG
TTGCTGAAAGTAGGAGAAAGTGCAT’) and Exon 14R (5#CAGGAAACAGCT
TGACCTCCTACAGTGTTTTCAGTTTCAAAAA3#). Sequencing used a spe-
cific forward sequencing primer (5#AGTCTTTCTTTGAAGCAGCAA3#) and
M13 reverse primer. Sequence analysis of bidirectional sequence traces
was performed using Mutation Surveyor version 2.28 (SoftGenetics). Candi-
date mutations were reamplified and sequenced from the original DNA sam-
ple for independent verification.
Genotyping of JAK2V617F allele
Genotyping was performed by MALDI-TOF MS analysis. Forward (5#-
ACGTTGGATGAGGCATTAGAAAGCCTGTAG-3#) and reverse (5#ACGTTG
GATGGCTTTCTCACAAGACATTTGG-3#) PCR primers and the primer
extension probe (5#-ACTCTCGTCTCCACAGA-3#) were designed using
SpectroDESIGNER software (Sequenom). Following PCR amplification, un-
incorporated nucleotides were dephosphorylated using shrimp alkaline
phosphatase (Amersham). Primer extension was carried out in the presence
of dATP, ddCTP, ddGTP, and ddTTP using ThermoSequence polymerase
(Amersham). Primer extension reaction products were loaded onto a
SpectroChip (Sequenom) and analyzed by MALDI-TOF (SpectroREADER,
Sequenom). SpectroTYPER (Sequenom) was used to analyze mass spectra
and determine genotypes based on peak intensities of the predicted primerCANCER CELL : APRIL 2005
A R T I C L Eextension products. A detailed protocol is available at http://www.hapmap.
org/downloads/genotyping_protocols.html.
Measurement of gene copy number by quantitative PCR
Quantitative PCR was performed using the Factor VIII locus as a reference
locus as previously described, except that an ABI 7700 sequence detector
was used (Wilke et al., 2000). A probe was designed for JAK2 exon 22
(5#TCCAATTTTAACTCTGTTCTCGTTCTCCACCA3#) using Primer Express
software (Applied Biosystems). Priming sequences were JAK2 F (5#-CAC
AGGGATCTGGCAACGA-3#), and JAK2 R (5#-TTGTGGCAAGACTTTGGT
TAACC-3#).
Amplification of sample DNA and of male reference DNA was prepared
in parallel and amplified on the same run for each sample in triplicate. A
single copy control was not available, so all samples were compared to
male reference DNA with 2 copies of the JAK2 locus. Copy number of the
JAK2 locus per haploid genome for each sample was determined by the
ratio of the means of relative copy number of the JAK2 locus and the Factor
VIII locus in males, and by multiplying this ratio by a factor of 2 in females.
Fluorescence in situ hybridization
Bone marrow fixed cells from patients with verified diagnosis of PV were
retrospectively selected from the collection at the Department of Human
Genetics (Leuven) for FISH. FISH was performed as described (Martin-
Subero et al., 2002). Two probes spanning the JAK2 locus, 197L5 and
725M10, were used (RPCI6 library, available at http://www.chori.org/
BACPAC). These patients were also genotyped for the presence of the
JAK2V617F mutation.
Expression vectors
The murine and human JAK2 cDNAs, respectively, were cloned into the
retroviral vector MSCV-Neo/Puro. The JAK2V617F mutation was generated
using site directed mutagenesis (Quikchange-XL, Stratagene) and con-
firmed by full-length DNA sequencing.
Cell culture
293T cells were grown in Dulbecco’s modified Eagle’s medium with 10%
fetal calf serum. Transient cotransfection of 293T cells and generation of
retroviral supernatant were performed as previously described (Schwaller
et al., 1998). Ba/F3 cells expressing the murine EPOR (BaF3-EPOR) (D’An-
drea et al., 1991) were grown in RPMI medium with 10% fetal calf serum
and 1 unit of EPO per milliliter. Ba/F3-EPOR cells were transduced with
retroviral supernatant containing either the MSCV-JAK2-Neo or MSCV-
JAK2V617F-Neo vectors, respectively, and then selected in G418 (1 mg/ml).
To assess for EPO sensitivity, the transduced Ba/F3-EPOR cells were
washed three times in phosphate-buffered saline (PBS) and cultured at con-
centrations of EPO 1 U/ml, 0.01 U/ml, 0.001 U/ml, or without EPO for 7
days, respectively. The number of viable cells was determined by trypan
blue exclusion. Leukemia cell lines HEL, K562, RPMI-8402, and MOLT16
were grown in RPMI medium with 10% fetal calf serum without cytokines.
For Western blotting, leukemia cell lines were incubated in the presence of
JAK inhibitor I (Calbiochem) for 4 hr. For dose response curves, leukemia
cell lines were incubated for 72 hr in the presence of JAK inhibitor I and the
number of viable cells was determined with the CellTiter 96 Aqueous One
Cell Proliferation Assay (Promega). The percentage of apoptotic cells at 72
hr was determined by flow cytometric analysis of annexin V-fluorescein and
propidium iodide (Roche) as previously described (Cools et al., 2004).
Western blotting
Cell lines were collected and lysed in lysis buffer (Invitrogen) and separated
by electrophoresis as previously described (Cools et al., 2003). The follow-
ing antibodies were used for Western blot analysis: anti-phospho-JAK2
(Cell Signaling), anti-JAK2 (polyclonal antibody raised against the JH1 do-
main of JAK2), antiphosphotyrosine (4G10) (Upstate), anti-phospho-STAT5
(Cell Signaling), anti-STAT5α (Cell Signaling), anti-phospho-ERK1/2 (Cell
Signaling), peroxidase-conjugated antimouse immunoglobulin (Amersham
Pharmacia Biotech), and peroxidase-conjugated antirabbit immunoglobulin
(Amersham Pharmacia Biotech).
Model of JAK2 JH2 domain structure
The SwissModel automated comparative protein modeling server (http://
swissmodel.expasy.org) was used to create an energy-minimized model ofCANCER CELL : APRIL 2005the JH2 domain of JAK2 (Schwede et al., 2003). The sequence for residues
Ser550 to Leu808 of JAK2 was submitted to SwissModel for a first ap-
proach mode search using the Protein Data Bank (http://www.pdb.org) de-
posited structure for Bruton’s tyrosine kinase (PDB accession code 1K2P)
as a three-dimensional template (sequence identity 26%) (Mao et al., 2001).
An energy-minimized model of the JH2 domain of JAK2 was determined
and manually checked for global reasonableness. The location of Val 617
in this model is in a similar conformation to the analogous valine residue in
other tyrosine kinase crystal structures that have been solved, e.g., Val256
in CSK (PDB accession code 1BYG) (Lamers et al., 1999).
Statistical methods
The association between mutational status, either heterozygous, homozy-
gous, or germline, and subject characteristics such as current age, age at
diagnosis, gender, race, comorbidity, physical functioning, prior thrombosis,
self-reported family history, and disease duration was tested by Chi square,
Fisher’s exact, or Wilcoxon rank-sum statistics as appropriate. Only p val-
ues less than 0.01 are reported because of multiple testing.
Supplemental data
Supplemental Data for this article can be found at http://www.cancercell.
org/cgi/content/full/7/4/387/DC1/.
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